In 2018 Natera paid a $11 million fine to the department over allegations of improper billing and sales of Panorama to federal Healthcare services between the years of 2013 to 2016. The Signatera CLIA test was introduced for clinical use in 2019. That same year, Natera introduced the Signatera molecular residual disease (MRD) test for research use only. In 2017, Natera launched the Vistara single-gene NIPT. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA." In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The following year, 2013, Natera launched the Panorama non-invasive prenatal test (NIPT). Natera's advanced carrier screening test, Horizon, launched in 2012. In 2010, the company introduced the Anora miscarriage (POC) test. Natera launched its first product, the Spectrum preimplantation genetic test, in 2009. Natera (previously Gene Security Network) was founded by Matthew Rabinowitz and Jonathan Sheena in 2004. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |